Publication at Faculty of Medicine in Pilsen |
2017
Abstract
The introduction of integrated PET/MRI imaging combining full magnetic resonance imaging and positron emission tomography is a new milestone in tissue imaging. As usual innovations in clinical practice generate new dilemmas.
The questions it poses are: when to use PET/MRI scanning, what radiopharmaceutical to use and how to optimize examination protocols. A range of new radiopharmaceuticals, in addition to 18F-fluorodeoxyglucose (18F-FDG), are now available for assessing and characterizing tissues.